Last updated: 11/04/2018 13:25:00
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on clinicaltrials.gov.
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
EudraCT ID
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Trial overview
Official title: A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects with FIGO Stage IVB or Recurrent or Persistent Cervical Cancer with Zero or One Prior Chemotherapy Regimen
Trial description: This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Progression-free survival (PFS) in Interim Analysis
Timeframe: From randomization until at least 35 PFS events in pairwise comparison of the three treatment arms (Interim Analysis; up to 52.14 weeks)
Progression-free survival (PFS) in Final Analysis
Timeframe: From Randomization until 105 total PFS events in combined population of two monotherapy arms (up to 85.57 weeks)
Secondary outcomes:
Overall survival
Timeframe: From Randomization (11 December 2006) until approximately 78% overall survival events at the time of the second overall survival update (3 March 2010) (up to 168.29 weeks)
Clinical benefit response
Timeframe: From Randomization until 105 total PFS events in combined population of two monotherapy arms (up to 85.57 weeks)
Response
Timeframe: From Randomization until 105 total PFS events in combined population of two monotherapy arms (up to 85.57 weeks)
Time to response
Timeframe: From Randomization until 105 total PFS events in combined population of two monotherapy arms (up to 85.57 weeks)
Duration of response
Timeframe: From Randomization until 105 total PFS events in combined population of two monotherapy arms (up to 85.57 weeks)
Safety and tolerability of pazopanib, lapatinib and the combination of pazopanib and lapatinib
Timeframe: From Randomization (11 December 2006) until last participant had last visit (28 July 2011) in combined population of two monotherapy arms (up to 241.43 weeks)
Interventions:
Drug: pazopanib (GW786034)
Drug: lapatinib (GW572016)
Enrollment:
228
Observational study model:
Not applicable
Primary completion date:
2011-28-07
Time perspective:
Not applicable
Clinical publications:
Monk BJ, Lopez LM, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber J, Ding J, Stutts MW, Pandite LN. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol, 2010;28(22):3562-3569.
Monk, BJ and Pandite, LN. Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. J Clin Oncol, 2011; 29(36): 4845.
Medical condition
Neoplasms, Uterine Cervix
Product
lapatinib, pazopanib
Collaborators
Not applicable
Study date(s)
November 2006 to July 2011
Type
Interventional
Phase
2
Participation criteria
Sex
Female
Age
18+ years
Accepts healthy volunteers
No
- A subject will be eligible for inclusion in this study only if all of the following criteria are met:
- Signed, written informed consent prior to performing any study-related procedures
- A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- Neuroendocrine or small cell carcinoma of the cervix.
Inclusion and exclusion criteria
Inclusion criteria:
- A subject will be eligible for inclusion in this study only if all of the following criteria are met:
- Signed, written informed consent prior to performing any study-related procedures
- Female subjects ≥18 years of age
- FIGO Stage IVB, or recurrent or persistent cervical cancer
- Life expectancy of at least 12 weeks
- ECOG status of 0 or 1.
- Histologically confirmed FIGO Stage IVB, or recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy
- Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be ≥ 20 mm when measured by conventional techniques, including palpitation, plain x-ray, CT and MRI, or ≥10 mm when measured by spiral CT.
- At least one "target lesion" to be used to assess response as defined by Response Evaluation Criteria in Solid Tumors (RECIST; Terasse, 2000). Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy.
- Received 0 or 1 prior chemotherapy regimen for metastatic disease.
- Note: Chemotherapy given in combination with radiation therapy as a radiosensitizer does not count toward this prior therapy limit
- Recovered from the effects of surgery or chemotherapy. At least three weeks must have elapsed from the last administration of chemotherapy.
- Adequate organ and bone marrow function as defined in Table 1.
- Table 1:(Definitions for Adequate Organ Function)
- System:(Laboratory Values)
- Hematologic: Absolute neutrophil count (ANC)(≥ 1.5 X 109/L)Hemoglobin1(≥9 g/dL)Platelets(≥100 X 109/L)
- Hepatic: Total bilirubin (≤1.5 X ULN)AST and ALT (≤2.5 X ULN)
- Renal: Calculated creatinine clearance2 (≥50 mL/min)
- Urine protein3 (Negative, trace or +1 by dipstick urinalysis or <1.0 gram determined by 24 hour urine protein analysis.)
- Subjects may not have had a transfusion within 7 days of screening assessment.
- Calculated by Cockcroft Gault formula See Appendix 7: Renal Function Tests
- A patient should first be screened with dipstick urinalysis. If urine protein by dipstick analysis is ≥2+, then a 24-hour urine protein must be assessed and 24 hour urine protein must be <1 g protein to be eligible.
- Ability to swallow and retain oral medication.
- A female is eligible to enter and participate in this study if she is of:
- Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had:
- A hysterectomy
- A bilateral oophorectomy (ovariectomy)
- A bilateral tubal ligation
- Is post-menopausal (total cessation of menses for ≥ 1 year)
- Childbearing potential, has a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception. GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows:
- An intrauterine device with a documented failure rate of less than 1% per year.
- Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
- Complete abstinence from sexual intercourse for 14 days before exposure to investigation product, through the dosing period, and for at least 21 days after the last dose of investigational product.
- Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide). Note: Oral contraceptives are not reliable due to potential drug-drug interactions.
- Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow-up as outlined in the protocol. Procedures conducted as apart of routine clinical management of the patient (e.g., blood count, imaging study) and obtained prior to signed informed consent may be utilized for screening purposes provided these tests are obtained as specified in the protocol
Exclusion criteria:
- A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- Neuroendocrine or small cell carcinoma of the cervix.
- Prior use of any biologic therapy with VEGF, VEGFR, or ErbB1/ErbB2 inhibitors.
- Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization).
- Concurrent treatment with an investigational agent or participation in another clinical trial.
- Use of an investigational anti-cancer drug within 28 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.
- Has taken or is taking prohibited medications listed in the protocol.
- Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with patient's safety, obtaining informed consent or compliance to the study.
- History of another malignancy. Note: Patients who have had another malignancy and have been disease-free for 5 years, or patients with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.
- History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis. Routine screening with CNS imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated.
- Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.
- Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to beginning therapy.
- Presence of uncontrolled infection.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib.
- Corrected QT interval (QTc) prolongation defined as QTc interval > 470 msecs.
- History of any one of the following cardiac conditions within the past 6 months:
- Cardiac angioplasty or stenting
- Myocardial infarction
- Unstable angina
- History of cerebrovascular accident or pulmonary embolus within the past 6 months.
- Has Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system (See Appendix 6)
- Poorly controlled hypertension (systolic blood pressure (SBP) of ≥ 140mmHg, or diastolic blood pressure (DBP) of ≥ 90mmHg).
- Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. The blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 24 hours. The mean SBP/DBP values from both BP assessments must be < 140/90mmHg in order for a subject to be eligible for the study.
- History of untreated deep venous thrombosis (DVT) within the past 6 months (e.g. calf vein thrombosis).
- Note: Patients with recent DVT who are treated with therapeutic anti-coagulant agents (excluding therapeutic warfarin) for at least 6 weeks are eligible.
- Presence of any non-healing, non-tumor related wound, fracture, or ulcer, or the presence of symptomatic peripheral vascular disease.
- Subjects with bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage.
- Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study; minor surgical procedures such as fine needle aspiration or core biopsy within 1 week prior to beginning therapy are also excluded.
- Unable to swallow and retain orally administered medication.
- Pregnant or lactating female.
Trial location(s)
Location
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73104
Status
Study Complete
Location
GSK Investigational Site
Stanford, California, United States, 94305-5317
Status
Study Complete
Location
GSK Investigational Site
La Laguna (Santa Cruz de Tenerife), Spain, 38320
Status
Study Complete
Location
GSK Investigational Site
Saarbruecken, Saarland, Germany, 66113
Status
Study Complete
Location
GSK Investigational Site
Chattanooga, Tennessee, United States, 37403
Status
Study Complete
Location
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39108
Status
Study Complete
Location
GSK Investigational Site
Augusta, Georgia, United States, 30912
Status
Study Complete
Location
GSK Investigational Site
Rosario, Santa Fe, Argentina, S2000KZE
Status
Study Complete
Location
GSK Investigational Site
Albuquerque, New Mexico, United States, 87131-5276
Status
Study Complete
Location
GSK Investigational Site
Boston, Massachusetts, United States, 02115
Status
Study Complete
Location
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 4E6
Status
Study Complete
Location
GSK Investigational Site
Orange, California, United States, 92868
Status
Study Complete
Location
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina, C1405CUB
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90033
Status
Study Complete
Location
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1185AAT
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10016
Status
Study Complete
Location
GSK Investigational Site
Tucuman, Tucumán., Argentina, 4000
Status
Recruitment Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
No longer a GSK study
Actual primary completion date
2011-28-07
Actual study completion date
2011-28-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website